Saudi Arabia Warns Oil Prices Could Surge Past $180 a Barrel Amid U.S.-Israel-Iran Conflict 
Japan's Major Companies Lead Strong Wage Growth for Fourth Consecutive Year 
Gold Prices Stabilize but Head for Worst Weekly Drop in Six Years Amid Iran War Inflation Fears 
Goldman Sachs Delays Bank of England Rate Cut Forecast Amid Middle East Inflation Risks 
Oil Prices Surge Past $100 as U.S.-Israel War on Iran Threatens Global Energy Supply 
Oil Prices Slide as U.S. Eyes Iranian Supply Relief Amid Middle East Tensions 
U.S. Stock Futures Steady as Wall Street Retreats on Oil Volatility and Fed Rate Outlook 
Apple Defies China's Smartphone Slump with Strong Early 2026 Sales 
Samsung Bets Big on AI-Driven Chip Demand in 2025 
Alibaba Bets on AI Agents to Unify Its Vast Digital Ecosystem 
Japan's Parliament Backs Dovish BOJ Board Members, Raising Questions on Rate Hike Path 
Malaysia Semiconductor Industry Eyes Helium Supply Risks Amid Middle East Conflict 
Xiaomi Shares Drop After SU7 Launch as Margin Concerns Weigh on Investors 
DOJ Antitrust Chief Rejects Political Fast-Track for Paramount-Skydance Deal 
Yen Slides Near Two-Year Low as Fed Holds Rates Amid Middle East Tensions 
Elon Musk Confirms SpaceX, xAI, and Tesla Will Continue Large-Scale Nvidia Chip Orders 
In a landmark move, Samsung Biologics and Pfizer Inc. have entered into a strategic $409 million contract manufacturing organization (CMO) agreement. This record-setting deal enlists Samsung Biologics to produce a range of biosimilar drugs originally developed by Pfizer, furthering global access to essential medicines.
The Korea Times reported that under the contract, Samsung Biologics will manufacture biosimilars made by Pfizer. These are biopharmaceutical medical products that are identical to the original product, which means the Korean biotech firm will replicate certain drugs originally made by Pfizer.
The biosimilars that Samsung Biologics will produce for the New York-based pharmaceutical and biotechnology firm include medical drugs for inflammation, tumors, and the immune system. The company built its fourth production plant in Incheon, South Korea, recently, so it is likely to be used for the fulfillment of the said CMO agreement.
“We are pleased to extend the strategic collaboration with Pfizer as we share and support their strong vision to bring innovative solutions for patients around the globe,” Samsung Biologics’ president and chief executive officer, John Rim, said in a press release. “This new meaningful partnership comes just as our Plant 4 is fully completed early this month as we had previously committed and are on the move for future expansion into our second campus in order to provide our clients with even more flexible and advanced manufacturing technology.”
Pfizer’s chief global supply officer, executive vice president, Mike Dermott, added, “Pfizer is excited to continue our strategic partnership with Samsung Biologics Ltd. that aims to enable greater access to medicines for more patients across the world. This commitment is a reflection of Pfizer’s trust in the Korean Pharmaceutical industry to address emerging health challenges.”
Meanwhile, the partnership between Samsung Biologics and Pfizer has set a new record for the latter and the entire history of biopharma in South Korea. This is because it is the largest single contract to ever be recorded in the country.
Photo by: Samsung Biologics Newsroom
